Results 61 to 70 of about 602,416 (352)

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64

Pharmaceuticals, 2023
Understanding the physicochemical properties of antibody–drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage.
Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Kimiteru Ito, Tatsuya Higashi, Hiroaki Kurihara, Makoto Ueno   +12 more
doaj   +1 more source

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Drugs in R&D, 2018
Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global ...
Bilal H. Lashari, Yazhini Vallatharasu, Lakshmi Kolandra, Mohsin Hamid, Dipesh Uprety   +4 more
doaj   +1 more source

Morphine activates neuroinflammation in a manner parallel to endotoxin [PDF]

, 2012
Opioids create a neuroinflammatory response within the CNS, compromising opioid-induced analgesia and contributing to various unwanted actions. How this occurs is unknown but has been assumed to be via classic opioid receptors.
A. A. Somogyi, A. J. de Jesus, A. Reddy, Barochia, Bevan, Bokhari, Dziarski, H. Yin, Hargreaves, Hoshino, Hutchinson, Hutchinson, Hutchinson, Hutchinson, Hutchinson, Hutchinson, J. Thomas, Jacquet, Joce, K. Cheng, K. Ramos, Kirikae, L. C. Loram, L. R. Watkins, Lewis, Li, Liu, Liu, M. R. Hutchinson, Manavalan, Milligan, Nagyoszi, Narita, Ohto, Park, Resman, Rice, Slivka, Takeuchi, Viriyakosol, Watkins, X. Wang, Youn   +42 more
core   +2 more sources

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Journal of Clinical Oncology, 2020
PURPOSE This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibody ...
R. Hassan, G. Blumenschein, K. Moore, A. Santin, H. Kindler, J. Nemunaitis, S. Seward, Anish Thomas, Stella K. Kim, P. Rajagopalan, A. Walter, D. Laurent, B. Childs, N. Sarapa, C. Elbi, J. Bendell   +15 more
semanticscholar   +1 more source

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Breast Cancer: Targets and Therapy, 2021
Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G ...
Linehan AS, Fitzpatrick OM, Morris PG
doaj  

Crosstalk between the ribosome quality control‐associated E3 ubiquitin ligases LTN1 and RNF10

FEBS Letters, EarlyView.
Loss of the E3 ligase LTN1, the ubiquitin‐like modifier UFM1, or the deubiquitinating enzyme UFSP2 disrupts endoplasmic reticulum–ribosome quality control (ER‐RQC), a pathway that removes stalled ribosomes and faulty proteins. This disruption may trigger a compensatory response to ER‐RQC defects, including increased expression of the E3 ligase RNF10 ...
Yuxi Huang, Satoshi Hashimoto, Sota Ito, Chisato Kikuguchi, Miho Hoshi, Kiyoshi Yamaguchi, Yoichi Furukawa, Toru Suzuki, Toshifumi Inada   +8 more
wiley   +1 more source

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]

, 2016
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Miller, Kathy, Molnar, Istvan, Reynolds, Joseph G, Riahi, Kaveh, Tripathy, Debu, Verma, Sunil, Wickham, Thomas J, Yardley, Denise A   +10 more
core   +2 more sources

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). [PDF]

PLoS ONE, 2015
The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung, Jang-Fang Kuo, Wan-Chen Wei, King-Jen Chang, Wei-Ting Chao   +4 more
doaj   +1 more source